Drug intelligence / Profile preview

18F-AlF-ETN

Development stage: Preclinical
Modality: Cyclic Peptides → Modified Peptides → Peptides, Antibody-Radionuclide Conjugates → Antibody Conjugates → Antibody-Based Therapeutics
Administration: Intravenous

Overview

18F-AlF-ETN is a radiolabeled bicyclic peptide designed for positron emission tomography (PET) imaging. It specifically targets the erythropoietin-producing hepatocellular receptor A2 (EphA2), a receptor overexpressed in several cancers, including prostate cancer and pancreatic ductal adenocarcinoma (PDAC). The compound was developed to address limitations of prostate-specific membrane antigen (PSMA) PET/CT imaging, particularly in patients with low PSMA expression due to androgen deprivation therapy or neuroendocrine differentiation. Preclinical studies have demonstrated that 18F-AlF-ETN selectively accumulates in EphA2-positive tumors, providing high tumor-to-background contrast and enabling detection of PSMA-negative prostate cancer as well as other EphA2-expressing malignancies[1][3][4][5]. The agent shows high in vivo stability and enhanced imaging contrast in animal models[3].

Other names: [18F]AlF-ETN

Targets

EPHA2 (Ephrin type-A receptor 2)

Beyond the preview

Go deeper on 18F-AlF-ETN.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on 18F-AlF-ETN.

Explore the full profile